Literature DB >> 19158559

Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02% mitomycin C in primary pterygium excision.

Alvin L Young1, Patrick M K Tam, Gloria Y S Leung, Lulu L Cheng, Philip T H Lam, Dennis S C Lam.   

Abstract

PURPOSE: To describe the novel use of combined conjunctival rotational autograft (CRA) and intraoperative 0.02% mitomycin C (MMC) in the treatment of primary pterygium and to evaluate its safety and efficacy.
METHODS: Prospective interventional case series comparing with historical controls was conducted. Patients with primary pterygium underwent pterygium excision, MMC was applied to the scleral bed after the surface conjunctiva was harvested, and the CRA was sutured back with a 180-degree rotation. Patients were followed for a minimum of 1 year.
RESULTS: Sixty-seven eyes from 67 patients participated in the study, of which 31 (46.3%) were men and 36 (53.7%) were women. The mean age was 58 +/- 10.6 years, (range 36-79 years). There were 2 recurrences (3%), one occurring at month 3 and the other at month 9. Compared with historical controls, CRA-MMC resulted in significantly fewer recurrences than MMC alone (P = 0.005) when adjusted for age and was equally effective when compared with limbal-conjunctival autografts. The main postoperative problem was graft injection, which was noted in 41 eyes (61%) at 1 year.
CONCLUSIONS: To the best of our knowledge, this was the first study on the combined use of CRA and MMC in the treatment of primary pterygium. CRA with MMC was found to be effective in the prevention of recurrence. Although injection remained as a cosmetic concern, it was a safe alternative to limbal-conjunctival autograft in cases where mobilizing autologous conjunctival tissue would not be feasible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158559     DOI: 10.1097/ICO.0b013e318187544d

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  [Pterygium. Etiology, clinical aspects and novel adjuvant therapies].

Authors:  L M Heindl; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

2.  Role of oxidative stress and vascular endothelial growth factor expression in pterygium pathogenesis and prevention of pterygium recurrence after surgical excision.

Authors:  Sameh Mohamed Elgouhary; Hesham Fouad Elmazar; Mariana Ibrahim Naguib; Noha Rabie Bayomy
Journal:  Int Ophthalmol       Date:  2020-06-06       Impact factor: 2.031

Review 3.  Mitomycin C in pterygium treatment.

Authors:  Thiago Gonçalves Dos Santos Martins; Ana Luiza Fontes de Azevedo Costa; Milton Ruiz Alves; Roger Chammas; Paulo Schor
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

4.  [Pterygium: pathogenesis, diagnosis and treatment].

Authors:  Alexander C Rokohl; Ludwig M Heindl; Claus Cursiefen
Journal:  Ophthalmologe       Date:  2021-03-29       Impact factor: 1.059

5.  Subconjunctival bevacizumab for primary pterygium excision; a randomized clinical trial.

Authors:  Mohammad-Reza Razeghinejad; Mohammad Banifatemi
Journal:  J Ophthalmic Vis Res       Date:  2014-01

6.  Pterygium surgery using the principle of contact inhibition: results of 13 years' experience.

Authors:  Tsutomu Hara; Takako Hashimoto; Takeshi Hara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-28       Impact factor: 3.117

7.  Surgical outcome of conjunctival rotational autograft-mitomycin C (MMC) versus free conjunctival autograft-MMC for pterygium removal: A randomized clinical trial.

Authors:  Shahram Bamdad; Anis Shamsi Kooshki; Masoud Yasemi
Journal:  Electron Physician       Date:  2017-12-25

Review 8.  How to minimize pterygium recurrence rates: clinical perspectives.

Authors:  Raffaele Nuzzi; Federico Tridico
Journal:  Clin Ophthalmol       Date:  2018-11-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.